Detalles de la búsqueda
1.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet;
397(10277): 892-901, 2021 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33676628
2.
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Future Oncol;
18(29): 3245-3254, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35950603
3.
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Oncol;
21(12): 1661-1672, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33271095
4.
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Cancer Gene Ther;
31(4): 517-526, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38146006
5.
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.
JCO Clin Cancer Inform;
7: e2200164, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37352479
6.
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).
J Clin Oncol;
40(23): 2530-2538, 2022 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35167329
7.
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results.
Cancers (Basel);
13(13)2021 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34206826
8.
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Cancer Med;
7(6): 2288-2298, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29582557
Resultados
1 -
8
de 8
1
Próxima >
>>